Tirzepatide

Tirzepatide (brand names Mounjaro and Zepbound) is a once-weekly injectable GIP and GLP-1 receptor agonist used to treat type 2 diabetes and chronic weight management. By reducing appetite and slowing stomach emptying, it helps adults lose up to 20% of their body weight and improves glycemic control. Common side effects include nausea, diarrhea, vomiting, and constipation. BNF +5

Key Details

• • Uses: Treatment of type 2 diabetes and long-term weight management in adults with obesity or overweight (BMI
    ≥

    ≥
    27-30
    kg/m2

    𝑘𝑔/𝑚2
    ).

• Administration: Self-administered subcutaneous (under the skin) injection, usually in the abdomen, thigh, or upper arm, once weekly.

• Dosage: Starts at 2.5 mg, with titration in 2.5 mg increments every 4 weeks to a maintenance dose of 5, 10, or 15 mg.

• Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, injection site reactions, and potential fatigue.

• Long-Term Effects: Studies indicate no unexpected safety signals over a 176-week period. It may also reduce the risk of developing type 2 diabetes by 94% in high-risk individuals.

• Contraindications: Should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 
  NHS England +5

Important Information
Tirzepatide is most effective when paired with lifestyle changes, such as a reduced-calorie diet and increased physical activity. It may interact with oral contraceptives and other diabetes medications